Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Monoclonal Antibody MGA271

Known as: MGA271 
An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.
TPS2596Background: Enoblituzumab, is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of… Expand
2016
2016
The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.
256 Background: B7-H3 (CD276), part of the B7 superfamily, has been shown to play an immunomodulatory role, however its… Expand
Highly Cited
2015
Highly Cited
2015
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms…
Meeting abstracts MGA271 is a humanized IgG1 monoclonal antibody-targeting B7-H3 (CD276), a member of the B7 family. MGA271 has… Expand
2015
2015
A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung…
Meeting abstracts MGA271 is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7… Expand
Highly Cited
2012
Highly Cited
2012
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Purpose: The goal of this research was to harness a monoclonal antibody (mAb) discovery platform to identify cell-surface… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2012
2012
Abstract 2725: Preclinical development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent anti-tumor activity
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Antigens that are tumor-specific or over-expressed… Expand
2012
2012
Cancer Therapy : Preclinical Development of an Fc-Enhanced Anti – B 7-H 3 Monoclonal Antibody with Potent Antitumor Activity
Purpose: The goal of this research was to harness a monoclonal antibody (mAb) discovery platform to identify cell-surface… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE